Company
Description
Shenzhen Immuno Cure Biomedical is a wholly-owned subsidiary of Immuno Cure, specializing in the R&D of innovative immunotherapies for frontier applications in infectious diseases, malignant tumors, and inflammatory disorders. Its core pipeline includes the world's first therapeutic HIV vaccine ICVAX, a nucleic acid-based vaccine, and an anti-Δ42PD1 blocking antibody for the treatment of solid tumors. The company is dedicated to establishing a standardized preclinical validation platform to accelerate the clinical translation and commercialization of its core technology platforms.
